Excellos operates as a Contract Development and Manufacturing Organization (CDMO) specializing in cell therapy, providing comprehensive services from donor management to the commercialization of cell-based therapies. The company emphasizes the importance of cell potency and success in clinical trials by utilizing a proprietary platform called Excellos 360, which offers deep cell characterization. This platform goes beyond standard screening by delivering a detailed immune profile for each donor, assessing the metabolic and effector potential of their cells. Excellos sources a diverse range of high-retention donors, ensuring that the starting materials meet the specific needs of various therapeutic programs, including TIL therapy, CAR-T/NK therapies, and TCR therapy.

Excellos is built on a foundation of over 70 years of experience in blood and tissue collection, having originated from the San Diego Blood Bank. The company operates under stringent cGMP production standards within ISO 7 cleanrooms, ensuring that custom donor cells are processed, expanded, and cryopreserved with high quality. Excellos also provides extensive regulatory compliance support and quality assurance, including Quality by Design (QBD) and Manufacturing by Design (MBD) principles. Their offerings include a range of leukapheresis-derived products and services tailored to meet the needs of clients at various stages of therapeutic development, from discovery to clinical and commercial phases.

United States

Excellos accelerates gene therapies by improving the quality, breadth, and variance of donor samples, and providing end-to-end cell therapy services: from customized collection to engineered working cell banks. Our proprietary Excellos 360 technology provides deep characterization of cells to better match patient and therapeutic development needs.

Excellos

Company Details